{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:39:48Z","timestamp":1775162388144,"version":"3.50.1"},"reference-count":0,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":510,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Phospholipase A<jats:sub>2<\/jats:sub> (PLA<jats:sub>2<\/jats:sub>) and its enzymatic products free fatty acids (FFAs) and 2\u2010lysolecithin are physiological constituents of bile. Their role in the crystallization of cholesterol in gallbladder bile of patients with cholesterol gallstones is still controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>To clarify this issue we evaluated the activity of PLA<jats:sub>2<\/jats:sub> and the concentration and pattern of FFAs in the gallbladder bile of cholesterol stone patients. We furthermore added PLA<jats:sub>2<\/jats:sub>, FFAs and 2\u2010lysolecithin to isotropic gallbladder bile, determined the crystal observation time (COT) and counted the cholesterol crystals in a crystal growth assay for up to 21 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A PLA<jats:sub>2<\/jats:sub> activity of 1.8\u2003\u00b1\u20031.2\u2003U\u2003L<jats:sup>\u22121<\/jats:sup> and total FFA concentrations of 1.32\u2003\u00b1 0.71\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> were determined. After incubation of bile for 24\u2003h at 37\u2003\u00b0C total FFAs increased to 2.72\u2003\u00b1\u20031.29\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005). Biliary saturated and unsaturated FFAs were found in equal proportions before and after incubation, pointing to an additional presence of lipases other than PLA<jats:sub>2. <\/jats:sub>A COT of 1 day was observed in all gallbladder biles and increased to 1.7\u2003\u00b1\u20030.5 days after addition of 5\u2003U\u2003L<jats:sup>\u22121<\/jats:sup> of PLA<jats:sub>2<\/jats:sub> (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). An even higher COT of 2.5\u2003\u00b1\u20030.8 days was seen after addition of 5\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> of a \u2018biliary\u2019 mixture of FFAs (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005) but the COT remained unchanged after addition of 5\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> of 2\u2010lysolecithin. However, in the crystal growth assay in gallbladder bile addition of 5\u2003U\u2003L<jats:sup>\u22121<\/jats:sup> of PLA<jats:sub>2<\/jats:sub>, of 5\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> of \u2018biliary\u2019 FFAs and of 5\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> of 2\u2010lysolecithin decreased significantly the number of cholesterol crystals formed during follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>An elevated activity of PLA<jats:sub>2<\/jats:sub> in gallbladder bile may counteract the formation of cholesterol crystals through increased formation of FFAs and 2\u2010lysolecithin. However, regarding the comparatively low activity of PLA<jats:sub>2<\/jats:sub> in gallbladder bile PLA<jats:sub>2<\/jats:sub> seems to be of only minor pathophysiological importance in the formation of cholesterol gallstones.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2362.2000.00703.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T15:49:32Z","timestamp":1047397772000},"page":"715-721","source":"Crossref","is-referenced-by-count":7,"title":["Effects of phospholipase A<sub>2<\/sub>, free fatty acids and 2\u2010lysolecithin on the crystallization of cholesterol in gallbladder bile"],"prefix":"10.1111","volume":"30","author":[{"family":"Sch\u00f6ne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"J\u00fcngst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hernandez\u2010Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2362.2000.00703.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2362.2000.00703.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2362.2000.00703.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T17:55:47Z","timestamp":1698602147000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2362.2000.00703.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1046\/j.1365-2362.2000.00703.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2362.2000.00703.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}